Glucagon-Like Peptide-1 and the Islet β-Cell: Augmentation of Cell Proliferation and Inhibition of Apoptosis
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Type 2 diabetes is a heterogeneous disorder that develops as a result of relatively inappropriate insulin secretion often in the setting of defective insulin action (insulin resistance). The factors responsible for insufficient insulin production in patients with type 2 diabetes are complex and are thought to involve a combination of genetic and metabolic defects, including chronic hyperglycemia, increased levels of free fatty acids, and dyslipidemia, which contribute to an inability to sustain adequate insulin secretion, defective β-cell proliferation, and/or increased β-cell apoptosis (1). Studies of the natural history of type 2 diabetes inform us that a progressive decline in β-cell function is common in diabetic patients independent of the method of treatment (2). Hence, new approaches are clearly needed that not only control metabolic abnormalities such as dyslipidemia and hyperglycemia, but that also preserve β-cell function and mass, perhaps by increasing the number of newly formed β-cells and/or decreasing β-cell death. Emerging experimental evidence has confirmed that elevated levels of glucose and specific monounsaturated fatty acids may be deleterious to β-cell survival in short-term studies of human islets (3). Although detailed information about the relative balance of β-cell proliferation and apoptosis in pancreases from subjects with type 2 diabetes is not available, recent autopsy data suggest that a combination of inappropriately decreased β-cell mass and increased β-cell apoptosis in the diabetic pancreas may be more common than previously appreciated (4, 5). Hence, absolute or relative deficiency of β-cells occurs paradoxically at a time when enhanced functional β-cell mass and increased insulin production is needed to overcome insulin resistance. Not surprisingly, the progressive deterioration in β-cell function that accompanies type 2 diabetes has sparked interest in identifying factors that either promote formation of new β-cells or inhibit the death of vulnerable β-cells (1). Experimental studies carried out predominantly in rodents have demonstrated that IGFs, hepatocyte growth factor, pituitary adenylate cyclase-activating polypeptide, PTHrP, epidermal growth factor receptor agonists in combination with gastrin, and incompletely characterized proteins such as islet neogenesis-associated protein, are capable of enhancing β-cell mass in the setting of experimental diabetes. Hence, prolonged administration of these agents may expand β-cell mass, ultimately leading to increased insulin secretion and improved glycemic control. Similarly, growth factors may also expand the number of human islet cells in experimental culture systems (6, 7). Nevertheless, none of these proteins has been demonstrated to rapidly lower blood glucose and improve metabolic control in preclinical models of diabetes independent of their chronic effects on islet proliferation or β-cell survival. Hence, pharmaceutical development of molecules exhibiting β-cell growth factor-like activity that do not concomitantly acutely lower blood glucose remains highly challenging as it may take weeks or more likely months to determine their potential efficacy in diabetic human subjects. New data presented in the article by Farilla et al. (8) in this issue of Endocrinology now demonstrate that glucagon-like peptide-1 (GLP-1), a gut hormone derived from enteroendocrine L cells, inhibits cell death in freshly isolated human islets cultured in vitro for 5 d. The antiapoptotic effects of GLP-1 have previously been demonstrated in diabetic rodents, islet cell lines, purified rat β-cells, and heterologous cells expressing the GLP-1 receptor (9–12). Intriguingly, GLP-1 receptor activation also enhances neuronal survival in diverse cellular and animal models of neuronal toxicity, and elimination of GLP-1 receptor function in mice is associated with increased neurotoxicity after peripheral administration of kainic acid (13, 14). Furthermore, the antiapoptotic actions of GLP-1 are essential for β-cell survival in response to cellular injury, as mice with a disruption of the GLP-1 receptor gene exhibit enhanced β-cell death and more severe hyperglycemia after exposure to streptozotocin (10). Farilla et al. (8) added GLP-1 (10 nm) to human islet cells isolated from three independent donors and observed preserved islet morphology in the GLP-1-treated islets, whereas control islets exhibited a greater degree of degradation and loss of three-dimensional structure. GLP-1 treatment was also associated with reduced morphological features of β-cell apoptosis (nuclear condensation and fragmentation) and decreased expression of active caspase-3, an enzyme that plays an essential role in the final pathway leading to programmed cell death. The authors found that GLP-1-treated islets exhibited a progressive increase in the levels of the prosurvival protein bcl-2, which likely contributed to the antiapoptotic actions of GLP-1 in the islet cultures. GLP-
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It also promotes proliferation and reduces apoptosis of pancreatic β-cells, thereby maintaining their quality and functionality.130,218”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [218]
Citations
Cites
Shapiro, A. M. J., Lakey, J. R. T., Ryan, E. A., Korbutt, G. S., Toth, E., Warnock, G. L., Kneteman, N. M., & Rajotte, R. V. (2000) · New England Journal of Medicine · doi:10.1056/nejm200007273430401 · Cited by 5,237
β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297 · cited 2×
“As GLP-1 treatment of human diabetic subjects improves metabolic control resulting in reduction of hyperglycemia and a decrease in circulating fatty acids (25), GLP-1 may also indirectly attenuate islet glucotoxicity and lipotoxicity, thereby resulting in healthier -cells and reduced -cell death (Fig.”
BackgroundXu, G., Stoffers, D. A., Habener, J. F., & Bonner-Weir, S. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2270 · Cited by 1,209
Glucagon-like peptide-1 receptor is involved in learning and neuroprotection
During, M. J., Cao, L., Zuzga, D. S., Francis, J. S., Fitzsimons, H. L., Jiao, X., Bland, R. J., Klugmann, M., Banks, W. A., Drucker, D. J., et al. (2003) · Nature Medicine · doi:10.1038/nm919 · Cited by 851
Self-citationFarilla, L., Bulotta, A., Hirshberg, B., Li Calzi, S., Khoury, N., Noushmehr, H., Bertolotto, C., Di Mario, U., Harlan, D. M., & Perfetti, R. (2003) · Endocrinology · doi:10.1210/en.2003-0323 · Cited by 664 · cited 3×
“glucose-dependent insulin secretion (8).”
BackgroundInfluentialSelective β-Cell Loss and α-Cell Expansion in Patients with Type 2 Diabetes Mellitus in Korea
Yoon, K. H., Ko, S. H., Cho, J. H., Lee, J. M., Ahn, Y. B., Song, K. H., Yoo, S. J., Kang, M. I., Cha, B. Y., Lee, K. W., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020735 · Cited by 649
Glucagon-like Peptide-1 Receptor Signaling Modulates β Cell Apoptosis
Li, Y., Hansotia, T., Yusta, B., Ris, F., Halban, P. A., & Drucker, D. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209423200 · Cited by 589 · cited 2×
“glycemia after exposure to streptozotocin (10).”
BackgroundSelf-citationEnhancing Incretin Action for the Treatment of Type 2 Diabetes
Drucker, D. J. (2003) · Diabetes Care · doi:10.2337/diacare.26.10.2929 · Cited by 579
Self-citation
Cited by
Items 201–281 of 281
Pathogenesis of Type 2 Diabetes Mellitus
Kalin, M. F., Goncalves, M., & Fonseca, V. A. (2016) · Springer eBooks · doi:10.1007/978-3-319-20797-1_13-1 · Cited by 10
Pathogenesis of Type 2 Diabetes Mellitus
Kalin, M. F., Goncalves, M., John‐Kalarickal, J., & Fonseca, V. A. (2017) · Springer eBooks · doi:10.1007/978-3-319-20797-1_13-2 · Cited by 11
Winzell, M. S., & Åhrén, B. (2007) · Journal of Molecular Endocrinology · doi:10.1677/jme-07-0121 · Cited by 7
Lee, H. N., Hardy, J. C., Pool, E. H., Zhang, J., Kim, S. H., Buhl, W. F., Bruystens, J. G. H., Mehta, S., Taylor, S. S., & Zhang, J. (2025) · PLoS Biology · doi:10.1371/journal.pbio.3003262 · Cited by 8
Chen, C., Hsu, C.-M., Lin, C., Chou, A., & Jeng, L.-B. (2016) · PLoS ONE · doi:10.1371/journal.pone.0167321 · Cited by 6
Kamei, S., Kaneto, H., Tanabe, A., Kinoshita, T., Obata, A., Kimura, T., Hirukawa, H., Tatsumi, F., Shimoda, M., Kohara, K., et al. (2017) · Diabetes & Metabolism · doi:10.1016/j.diabet.2017.01.008 · Cited by 6
Type 2 Diabetes Mellitus: Epidemiology, Genetics, Pathogenesis, and Clinical Manifestations
Fonseca, V. A., & John‐Kalarickal, J. (2009) · Springer eBooks · doi:10.1007/978-0-387-09841-8_13 · Cited by 13
Watanabe, H., Fujishima, F., Yamazaki, Y., Imamura, M., Hijioka, S., Hara, K., Kuwahara, T., Yatabe, Y., Sakamoto, K., Shiga, H., et al. (2025) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-025-04098-2 · Cited by 6
Gao, H., Zhao, Q., Tang, S., Li, K., Qin, F., Song, Z., Pan, Y., Jin, L., & Zhang, Y. (2021) · Scientific Reports · doi:10.1038/s41598-021-83201-4 · Cited by 5
Targeting the Incretin System in Type 2 Diabetes Mellitus
Potenza, M. V., & Rayfield, E. J. (2009) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20112 · Cited by 6
GLP‐1 C‐terminal structures affect its blood glucose lowering‐function
Li, Y., Shi, C., Lv, Q.-J., Zhang, H., Biehu, L., Bian, G., Huang, Q., Zhang, W., Xue, X., Ren, X., et al. (2008) · Journal of Peptide Science · doi:10.1002/psc.997 · Cited by 5
Chen, C., Lin, C., & Kao, C. (2016) · Medicine · doi:10.1097/md.0000000000003481 · Cited by 6
A novel gene therapy platform for the treatment of type 2 diabetes and obesity
Lourie, J., Goraltchouk, A., Hollander, J. M., BERGER, N. J. A., Rosen, H. G., Fujishiro, A. A., Luppino, F., Seregin, A., Rhym, L. H., & Zou, K. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102739 · Cited by 6
Ruggeri, R. M., Grossrubatscher, E. M., Ciocca, E., Hasballa, I., Jaafar, S., Oldani, M., Rubino, M., Russo, F., Isidori, A. M., Colao, A. A. L., et al. (2025) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-025-09958-5 · Cited by 5
Role of endogenous incretin hormones, GLP-1 and GIP, in cardiovascular physiology
Trivedi, K., & Dolinsky, V. W. (2026) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2025-0163 · Cited by 7
Chae, H., Lee, M., Hwang, H., Kim, H. A., Kang, J., Kim, C., Lee, S.-J., & Ihm, S. (2013) · Transplant International · doi:10.1111/tri.12052 · Cited by 4
Antihyperglycemic and Antiobesity Effects of JAL2 on db/db Mice
Lee, I., Kim, K., Kim, K., Park, J., Jeong, H.-S., Kim, Y., Na, Y., Chung, W., Ahn, K.-S., Lee, S., et al. (2016) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2016/6828514 · Cited by 4
Morais, T., Patrício, B. G., Pereira, S. S., Andrade, S., Carreira, M. C., Casanueva, F. F., & Monteiro, M. P. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28719 · Cited by 5
Mechanisms of Beta-Cell Death in Diabetes
Donath, M. Y., & Ehses, J. A. (2008) · Springer eBooks · doi:10.1007/978-4-431-75452-7_5 · Cited by 4
Glycemic Control in the Metabolic Syndrome and Implications in Preventing Cardiovascular Disease
Gerich, J. E. (2006) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2006.4.315 · Cited by 5
Diabetes drugs and the incidence of solid cancers: a survey of the current evidence
Tuccori, M., Convertino, I., Galiulo, M. T., Marino, A., Capogrosso-Sansone, A., & Blandizzi, C. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1361401 · Cited by 5
Exenatide: incretin therapy for patients with Type 2 diabetes mellitus
Tahrani, A. A., Piya, M. K., & Barnett, A. H. (2008) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.3.6.671 · Cited by 5
Gao, H., Zhao, Q., Li, K., Qin, F., Yin, X., Lu, Z., Song, Z., Wu, Y., Shen, Y., Pan, Y., et al. (2021) · Experimental Cell Research · doi:10.1016/j.yexcr.2020.112454 · Cited by 3
Sridhar, A., Khan, D., Babu, G., Irwin, N., Gault, V. A., Flatt, P. R., & Moffett, R. C. (2024) · Peptides · doi:10.1016/j.peptides.2024.171254 · Cited by 6
Fiziologicheskaya rol' inkretinov:perspektivy lecheniya bol'nykhsakharnym diabetom 2 tipa
Galstyan, G. R. (2006) · Diabetes Mellitus · doi:10.14341/2072-0351-6183 · Cited by 2
Montemurro, C., Köhler, C. U., Uhl, W. H., Tannapfel, A., Schmidt, W. E., Bonora, E., & Meier, J. J. (2010) · Regulatory Peptides · doi:10.1016/j.regpep.2010.07.164 · Cited by 3
Barnett, A. H. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01440.x · Cited by 3
[Exenatide trials for the treatment of type 2 diabetes].
Landó, L. F., & CASELLINI, C. M. (2009) · PubMed · Cited by 6
Management of type 2 diabetes: the GLP‐1 pathway
Tahrani, A. A., Piya, M. K., & Barnett, A. H. (2008) · Future Prescriber · doi:10.1002/fps.39 · Cited by 3
Dipeptidyl Peptidase IV Inhibitors for Treatment of Diabetes
McIntosh, C. H. S., Kim, S. ‐., Pederson, R. A., Heiser, U. F., & Demuth, H. (2011) · Wiley eBooks · doi:10.1002/9780470910016.ch12 · Cited by 3
Exercise Suppresses Appetite in Obesity: A Biochemical, Metabolic, and Molecular Approach
Razi, O., Zamani, N., de Moraes, C., Laher, I., & Hadjicharalambous, M. (2025) · Applied Sciences · doi:10.3390/app15116191 · Cited by 6
Insulin/IGF signaling in islet biology and its therapeutic implications
Kim, H., & Kulkarni, R. N. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag014 · Cited by 2
Role of Mitochondria in β-Cell Function and Dysfunction
Maechler, P., Li, N., Casimir, M., Vetterli, L., Frigerio, F., & Brun, T. (2014) · Springer eBooks · doi:10.1007/978-94-007-6686-0_7 · Cited by 2
Metabolic resilience: liraglutide’s potential in alleviating depressive symptoms
Gammoh, O., Qnais, E. Y., Aljabali, A. A. A., Hatahet, T., & Alqudah, A. M. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-10641-w · Cited by 2
Altman, J., & Chevallier, J. (2007) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(07)74146-9 · Cited by 2
Treatment of obesity and diabetes with bariatric surgery
Whitlock, K. A., Gill, R. S., Switzers, N., Birch, D. W., & Karmali, S. (2013) · Global Epidemic Obesity · doi:10.7243/2052-5966-1-1 · Cited by 2
Glucagon-Like Peptide 1 Attenuates Lipotoxicity-Induced Islet Dysfunction in ApoE–/– Mice
Liu, F., Gong, L., Qin, W., Cui, C., Chen, L., & Zhang, M. (2020) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s262479 · Cited by 2
Schernthaner-Reiter, M. H., & Schernthaner, G. (2016) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2016.1151783 · Cited by 1
Using Gene Expression Signatures to Dissect Insulin Resistance Subtypes
Hayward, B., Konstantopoulos, N., & Ken, R. (2011) · InTech eBooks · doi:10.5772/22889 · Cited by 1
The Role of Central Nervous System Glucagon-Like Peptide-1 in the Regulation of Energy Balance
Barrera, J. G. (2009) · OhioLink ETD Center (Ohio Library and Information Network) · Cited by 1
Fujitani, Y. (2012) · Juntendō Igaku/Juntendo igaku · doi:10.14789/pjmj.58.490 · Cited by 1
Impact of sleeve gastrectomy on abnormalities in carbohydrate tolerance in obese adult.
Hedfi, I., Mahjoub, F., Amor, N. B., Berriche, O., Gamoudi, A., Karmous, I., Jerraya, H., Nouira, R., & Kamoun, H. J. (2021) · PubMed Central · Cited by 3
Incretin Mimetics in the Indian Context: Revisiting Exenatide
Tripathi, S. K., Dasgupta, S., Joshi, S., Mukherjee, S., & Samajdar, S. S. (2022) · Bengal Physician Journal · doi:10.5005/jp-journals-10070-7073 · Cited by 1
Combination pharmacotherapy with incretins: What works best and when?
Over, R., & Ratner, R. E. (2008) · Current Diabetes Reports · doi:10.1007/s11892-008-0063-5 · Cited by 1
Does Glucagon-Like Peptide-1 Have a Role in the Etiopathogenesis of Gestational Diabetes?
Demirpençe, M., Demirpençe, N., Tütüncüoğlu, P., Örük, G., Atalay, N. G., Görgel, A. F., Yilmaz, H., Arslan, B., & Bahçeci, M. (2016) · Endocrinology research and practice. · doi:10.4274/tjem.3079 · Cited by 2
Mitochondria and Metabolic Signals in β-Cells
Maechler, P. (2010) · Springer eBooks · doi:10.1007/978-1-4419-6956-9_3 · Cited by 3
The role of glucagon-like peptide-1 on food intake, glucokinase expression and fatty acid metabolism
Zhang, H. (2009) · Louisiana State University · doi:10.31390/gradschool_theses.3765 · Cited by 1
Pierantonelli, I. (2013) · Università Politecnica delle Marche (Università Politecnica delle Marche)
A global approach to dissecting lipid-induced impairment of liver gluconeogenesis
Hayward, B. J. (2013)
Novedades en terapia hipoglucemiante. Fármacos con acción incretina
Boillos, M. G., Pereg, V., & Burguera, B. G. (2008) · Endocrinología y Nutrición · doi:10.1016/s1575-0922(08)76266-1
Bariatric Surgery to Prevent and Treat Diabetes
Gill, R. S., Whitlock, K. A., Sandhu, R. K., Birch, D. W., & Karmali, S. (2011) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-011-0218-9
Saxagliptin a New Second Line Therapy After Metformin for the Treatment of Type 2 Diabetes
Palalau, A. I., Tahrani, A. A., Piya, M. K., & Barnett, A. H. (2010) · Clinical Medicine Reviews in Vascular Health · doi:10.4137/cmrvh.s4535
Holz, G. G., & Chepurny, O. G. (2005)
Non-insulin therapy of type 2 Diabetes Mellitus:
Lopes, Z. (2010)
Rodríguez, J. H., & Puig, M. E. L. (2013)
Sobrecarga oral con grasa insaturada y estrés oxidativo en sujetos con obesidad abdominal
Hidalgo, N., & Inmaculada, M. (2015) · Dialnet (Universidad de la Rioja)
Cummings, D. E., Overduin, J., Shannon, M. H., & Foster‐Schubert, K. E. (2005)
Impacts of bariatric surgery on type 2 diabetes mellitus
Yassin, M. A., Merdan, I., & Al-Gazgooz, F. (2019) · The Medical Journal of Basrah University · doi:10.33762/mjbu.2019.163355
Évolution du syndrome métabolique après sleeve gastrectomie chez un groupe d’obèses tunisiens
Jamoussi, H., Hedfi, I., Amor, N. B., Berriche, O., Boumefteh, S., Jarraya, H., Nouira, R., & Mahjoub, F. (2021) · Nutrition Clinique et Métabolisme · doi:10.1016/j.nupar.2020.11.004
Diabetes in the Bariatric Surgery Patient
Yenumula, P. R., Gonçalves, C. G., Brethauer, S. A., Kashyap, S. R., & Schauer, P. R. (2007) · Springer eBooks · doi:10.1007/978-0-387-68062-0_54
Kaji, N., Namekawa, J., Takagi, Y., Watanabe, A., Nemoto, S., Minami, Y., Katayanagi, A., Kobayashi, T., & Asai, F. (2022) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13629
Role of Mitochondria in β-Cell Function and Dysfunction
Maechler, P., Li, N., Casimir, M., Vetterli, L., Frigerio, F., & Brun, T. (2014) · Springer eBooks · doi:10.1007/978-94-007-6884-0_7-2
Role of Mitochondria in β-Cell Function and Dysfunction
Maechler, P., Li, N., Casimir, M., Vetterli, L., Frigerio, F., & Brun, T. (2013) · Springer eBooks · doi:10.1007/978-94-007-6884-0_7-1
Gut Microbiota Potential in Type 2 Diabetes
Irfan, S., Muzaffar, H., Anwar, H., & Jabeen, F. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.105616
Beta-cell mass adaptation to ileum nutrient flow. An experimental model.
Salas-Alvarez, J., Campos-Martinez, F. J., Camacho-Ramírez, A., Peña, C. M., Gomar, D. A., Ribelles-García, A., Pérez-Arana, G.-M., & Oliveira, J. A. P. (2023) · PubMed · doi:10.14670/hh-18-563
Impaired Physiological Regulation of ß Cells: Recent Findings from Type 2 Diabetic Patients
Irfan, S., Muzaffar, H., Mukhtar, I., Jabeen, F., & Anwar, H. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1003752
Fenske, R. J., Wienkes, H. N., Peter, D. C., Schaid, M. D., Hurley, L. D., Pennati, A., Galipeau, J., & Kimple, M. E. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae100
Anwar, H., Mukhtar, I., Muzaffar, H., Irfan, S., Saleem, S., & Ijaz, F. (2024) · Springer eBooks · doi:10.1007/978-981-97-3790-1_2 · Cited by 1
Comparative Outcomes in Metabolic Surgery: Diabetes and Cardiovascular Health
Lee, T. C., Flores, R. D. L., Yonge, J. D., & Stroud, A. (2024) · Springer eBooks · doi:10.1007/978-3-031-72309-4_26
Ahn, J., Kim, M., Min, S. H., Bae, H.-G., Bae, J. Y., Kwon, J., Yi, H., & Park, D. H. (2026) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2026.1900693
Sridhar, A., Palmer, E. S., Craig, S. L., Tanday, N., O'Harte, F. P. M., & Irwin, N. (2026) · Diabetologia · doi:10.1007/s00125-026-06863-7
BindingDB Entry 50034558: Novel heterocyclic DPP-4 inhibitors for the treatment of type 2 diabetes.
BindingDB (2012) · UC San Diego · doi:10.7270/q2sf2wn8
BindingDB (2010) · UC San Diego · doi:10.7270/q2rn37qf
BindingDB (2009) · UC San Diego · doi:10.7270/q2639pgg
Incretine e funzione insulare: fisiopatologia
Bonato, V., Cataldo, D., & Dotta, F. (2008) · L Endocrinologo · doi:10.1007/bf03344632
Metadata
- Authors
- Drucker, D. J.
- Affiliations
- University of Toronto (CA)
- Corresponding author
- Drucker, Daniel J.
- ORCID
- Drucker, Daniel J.
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2003-12-01
- Volume
- 144
- Issue
- 12
- Pages
- 5145-5148
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W2141880555
- Cited by
- 274
- References
- 39
- Citations by year
- 2026: 4 · 2025: 8 · 2024: 7 · 2023: 3 · 2022: 9 · 2021: 8 · 2020: 5 · 2019: 7 · 2018: 4 · 2017: 12 · 2016: 10 · 2015: 6 · 2014: 10 · 2013: 18 · 2012: 7
- FWCI
- 2.61
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Endoplasmic Reticulum Stress and Disease
- Keywords
- glucagon-like peptide-1, beta-cell proliferation, beta-cell apoptosis, type 2 diabetes, beta-cell mass, islet neogenesis, insulin secretion, insulin resistance, growth factors, islet transplantation, beta-cell preservation, monounsaturated fatty acids, hyperglycemia, parathyroid hormone-related protein, gastrin
- MeSH terms
- Animals, Cell Division, Glucagon, Humans, Islets of Langerhans, Peptide Fragments, Protein Precursors, Apoptosis, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.